All In Biotech

Drug Trial Radar · NCT06703606

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

A PHASE 1B OPEN-LABEL NON-RANDOMIZED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MARSTACIMAB TREATMENT FOLLOWING THE DISCONTINUATION OF EMICIZUMAB THERAPY IN ADOLESCENT AND ADULT PARTICIPANTS WITH SEVERE HEMOPHILIA A WITHOUT INHIBITORS.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

May 13, 2025

Primary completion

May 5, 2027

Study completion May 5, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn about safety, how the body processes marstacimab and how it works in patients with severe hemophilia A without inhibitors. Hemophilia A is rare bleeding disorder where the blood doesn't clot normally. This causes a person to bleed a lot, even from a small cut. These patients who are on emicizumab medicine for routine prophylaxis for at least 6 months, and desire to switch to marstacimab medicine. Inhibitors are antibodies that the immune system develops because it sees the infused clotting factor as a foreign substance that needs to be destroyed. Antibodies are proteins that eat up the activated factor before it has time to stop the bleeding. Prophylaxis are preventive medicines. This study is seeking for participants: * with severe Hemophilia A withouth inhibitors who are on emicizumab treatment for at least 6 months. * must be 12 to less than 75 years old * must have a body weight of at least 35 kilograms. The results from this study will serve as a guide to doctors and their hemophilia A patients who will change their medicines in the real-world clinical setting. Patients who can take part in the study will receive marstacimab medicine as weekly injections under the skin of 150 milligrams for 4 months. Study treatment with marstacimab will be initiated no earlier than 14 days after last dose of emicizumab. The study can last up to 6 months. The sponsor will provide marstacimab. Patients will continue their usual treatment with the infused clotting factor for their bleeds when taking part in the study. Roll-over into an optional study treatment extension period will be available to participants who wish to continue prophylaxis with marstacimab in countries where it is not commercially available.

Conditions

  • Severe Hemophilia A

Interventions

  • MARSTACIMABDrug

    Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of marstacimab-related adverse events (AEs)Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment
  2. Incidence of marstacimab-related serious AEs (SAEs)Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Altman Clinical and Translational Research Institute-IDS

    La Jolla, California · Recruiting

  • Altman Clinical and Translational Research Institute

    La Jolla, California · Recruiting

  • Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center

    Los Angeles, California · Recruiting

  • UCSD Center for Bleeding and Clotting Disorders

    San Diego, California · Recruiting

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina · Recruiting

  • ECU Health Medical Center

    Greenville, North Carolina · Recruiting

  • Nirmal Hospital Pvt Ltd.

    Surat, Gujarat, India · Recruiting

  • K J Somaiya Hospital & Research Centre

    Mumbai, Maharashtra, India · Recruiting

  • Istanbul Universitesi Tıp Fakultesi Onkoloji Enstitusu

    Fatih, İ̇stanbul, Turkey (Türkiye) · Recruiting

  • Ege University Faculty of Medicine Dean's Office

    Bornova, İzmir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.